501 related articles for article (PubMed ID: 35345673)
1. GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer.
Chen G; Luo D; Zhong N; Li D; Zheng J; Liao H; Li Z; Lin X; Chen Q; Zhang C; Lu Y; Chan YT; Ren Q; Wang N; Feng Y
Front Immunol; 2022; 13():857308. PubMed ID: 35345673
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of Glypican family genes in early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy and possible mechanisms.
Liu JQ; Liao XW; Wang XK; Yang CK; Zhou X; Liu ZQ; Han QF; Fu TH; Zhu GZ; Han CY; Su H; Huang JL; Ruan GT; Yan L; Ye XP; Peng T
BMC Gastroenterol; 2020 Dec; 20(1):415. PubMed ID: 33302876
[TBL] [Abstract][Full Text] [Related]
3. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
4. Pan-cancer analysis reveals correlation between RAB3B expression and tumor heterogeneity, immune microenvironment, and prognosis in multiple cancers.
Liu XS; Chen YL; Chen YX; Wu RM; Tan F; Wang YL; Liu ZY; Gao Y; Pei ZJ
Sci Rep; 2024 Apr; 14(1):9881. PubMed ID: 38688977
[TBL] [Abstract][Full Text] [Related]
5. GPC2 as a diagnostic and prognostic marker regulated progression of colorectal cancer.
Wang R; Lin X
Arab J Gastroenterol; 2024 Feb; 25(1):51-57. PubMed ID: 38220478
[TBL] [Abstract][Full Text] [Related]
6.
Zhang H; Liu J
Transl Cancer Res; 2024 Feb; 13(2):1026-1042. PubMed ID: 38482423
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of the oncogenic and immunological role of SPON2 in human tumors.
Tang J; Huang Q; Li X; Gu S
Medicine (Baltimore); 2023 Sep; 102(37):e35122. PubMed ID: 37713832
[TBL] [Abstract][Full Text] [Related]
8. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
Liu P; Wang X; Pan L; Han B; He Z
Front Immunol; 2022; 13():901784. PubMed ID: 35720327
[TBL] [Abstract][Full Text] [Related]
10. Pan-Cancer analysis shows that ACO2 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including hepatocellular carcinoma.
Wang Z; Zheng W; Chen Z; Wu S; Chang H; Cai M; Cai H
Front Oncol; 2022; 12():1055376. PubMed ID: 36531056
[TBL] [Abstract][Full Text] [Related]
11. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.
Li N; Fu H; Hewitt SM; Dimitrov DS; Ho M
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6623-E6631. PubMed ID: 28739923
[TBL] [Abstract][Full Text] [Related]
12. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
Front Genet; 2022; 13():993438. PubMed ID: 36685895
[No Abstract] [Full Text] [Related]
13. Comprehensively prognostic and immunological analysis of snail family transcriptional repressor 2 in pan-cancer and identification in pancreatic carcinoma.
Zhang D; Jiang Z; Hu J; Sun X; Zheng Y; Shen Y
Front Immunol; 2023; 14():1117585. PubMed ID: 37251370
[TBL] [Abstract][Full Text] [Related]
14. Systematic Pan-Cancer Analysis of KLRB1 with Prognostic Value and Immunological Activity across Human Tumors.
Cheng X; Cao Y; Wang X; Cheng L; Liu Y; Lei J; Peng W; Shi D
J Immunol Res; 2022; 2022():5254911. PubMed ID: 35028320
[TBL] [Abstract][Full Text] [Related]
15. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.
Foster JB; Griffin C; Rokita JL; Stern A; Brimley C; Rathi K; Lane MV; Buongervino SN; Smith T; Madsen PJ; Martinez D; Delaidelli A; Sorensen PH; Wechsler-Reya RJ; Karikó K; Storm PB; Barrett DM; Resnick AC; Maris JM; Bosse KR
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167467
[TBL] [Abstract][Full Text] [Related]
16. A Comprehensive Analysis of the Prognostic, Immunological and Diagnostic Role of CCNF in Pan-cancer.
Gao X; Bu H; Ge J; Gao X; Wang Y; Zhang Z; Wang L
J Cancer; 2023; 14(13):2431-2442. PubMed ID: 37670965
[No Abstract] [Full Text] [Related]
17. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
18. Multi-omics analysis of the oncogenic value of copper Metabolism-Related protein COMMD2 in human cancers.
Tai P; Wang Z; Chen X; Chen A; Gong L; Cheng Y; Cao K
Cancer Med; 2023 May; 12(10):11941-11959. PubMed ID: 36205192
[TBL] [Abstract][Full Text] [Related]
19. NALCN is a potential biomarker and therapeutic target in human cancers.
He J; Xu J; Chang Z; Yan J; Zhang L; Qin Y
Front Genet; 2023; 14():1164707. PubMed ID: 37152978
[No Abstract] [Full Text] [Related]
20. Pan-cancer analysis reveals potential of FAM110A as a prognostic and immunological biomarker in human cancer.
Zhong H; Shi Q; Wen Q; Chen J; Li X; Ruan R; Zeng S; Dai X; Xiong J; Li L; Lei W; Deng J
Front Immunol; 2023; 14():1058627. PubMed ID: 36923407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
